None listed
Conditions
Interventions
Procedure/Surgery : The proposed clinical trial is a study to evaluate the efficacy and safety of high-frequency therapy and chemotherapy therapy in combination with high-frequency therapy and chemoth
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. An adult between the ages of 20 and under the age of 80 who can understand the clinical trial and who voluntarily agrees to participate in the trial and who can sign a written consent form. 2. Patients who have been confirmed for pancreatic cancer using biopsy 3. Estimated life expectancy of 6 months or more 4. Patients with locally advanced pancreatic cancer according to NCCN criteria (determined by CT, MRI, or PET-CT results) 5. If EUS-RFA is available at the time of screening (as determined by the gastroenterologist) 6. There is no uncontrolled active infection, except for chronic viral hepatitis under antiviral treatment. 7. Eastern Oncology Joint Research Group (ECOG) performance status is 0 or 1 8. Weight > 30 kg 9. Normal organ and bone marrow function 10. The subject has the will and ability to comply with the clinical trial plan during the trial period, including follow-up and receiving dosing and scheduled visits and tests. 11. In the absence of any other malignant disease, except for non-melanoma skin cancer, cervical epithelial carcinoma, localized prostate cancer or thyroid papillary cancer, or all other cancers previously treated for healing purposes for more than 5 years without evidence of recurrence;
Exclusion criteria
Exclusion criteria: 1. If there is an internal or psychiatric condition that threatens the subject's ability to provide consent or comply with the clinical trial plan, or if there is a history of non-adherence; 2. When the gastrointestinal tract is closed 3. If you have a myocardial infarction within 6 months prior to administration of the test drug and have other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled high blood pressure) 4. If, in the opinion of the examiner, there is evidence of a severe or uncontrolled systemic disease or co-occurrence that makes it undesirable for the test subject to participate in the trial or jeopardizes compliance with the clinical trial plan; 5. Adenocarcinoma/squamous complex, neuroendocrinoma 6. If you have a history of allogeneic organ transplantation 7. If you have a history of other primary malignant tumors except the following: a. Malignant tumors that have been treated for healing purposes and have no known active disease for more than 5 years prior to the first dose of IP, and have a low potential risk of recurrence b. Disease unfounded and properly treated non-melanoma skin cancer or malignant sunspots c. Endothelial carcinoma that has no basis for the disease and has been properly treated 8. Pregnant or breastfeeding female test subjects, or childbearing men or women who are not willing to use effective contraceptive methods from screening until 90 days after the last dose of chemotherapy after surgery. 9. If an allergy or hypersensitivity is known to any of the test drugs or to any of the test drug additives 10. If the tester determines that the test subject is not suitable to participate in the test and that the test subject is unlikely to comply with the test procedures, restrictions and requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1yr progression free survival, PFS | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, OS; progression free survival, PFS; RECIST v1.1; R0, R1; NCI-CTCAE v5.0 | — |
Countries
Korea, Republic of
Contacts
Public ContactDong wan Seo
Asan Medical Center
Outcome results
None listed